Proposed Rule Aims to Make Drug Pricing More Transparent

$939.71.That is the list price for a one-month prescription for Abilify, a brand-name drug primarily used to treat schizophrenia and bipolar disorder. Under a proposed rule recently published by the U.S. Department of Health and Human Services (HHS), $939.71 is also the price that would appear on the television screen during an Abilify advertisement. Seeking to enhance pricing transparency, the proposed rule would require television commercials for any Medicare- or Medicaid-covered drug selling for more than $35 to display the list price of a thirty-day supply. HHS Secretary Alex Azar touts this proposed measure as a step toward lower medical costs. By requiring manufacturers to display drugs’ list prices during television advertisements, consumers will be better equipped to make choices about their health care, which in turn will put pressure on manufacturers to lower prices or at least prevent them from rising. In fact, Azar compares the measure to the Automobile…

Read more detail on Recent Administrative Law posts –

This entry was posted in Administrative law and tagged , , , , , . Bookmark the permalink.

Leave a Reply